Reply

Gastroenterology

Volumn 131, Issue 1, 2006, Pages 332-333

  Dienstag, Jules L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONSENSUS INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN;

CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; ETHNOLOGY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HEPATITIS C; HUMAN; INJECTION; LETTER; MEDICAL ETHICS; MEDICAL EXPERT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGISTRATION; TREATMENT RESPONSE; VALIDATION PROCESS;

EID: 33745737325     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.05.034     Document Type: Letter

References (5)

1. National Institutes of Health Consensus Development Conference. Management of hepatitis C. Hepatology 26 Suppl 1 (1997) 1S-156S
2. National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 36 Suppl 1 (2002) S3-S20
3. Strader D., Wright T., Thomas D., and Seeff L. Diagnosis, management and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
4. Sjogren M.H., Sjogren R.W., Hotzmuller K., et al. Interferon alfacon-1 and ribavirin versus interferon alpha 2b and ribavirin in the treatment of chronic hepatitis C. Dig Dis Sci 50 (2005) 727-732
5. Cornberg M., Hadem J., Herrmann E., et al. Treatment with daily consensus interferon plus ribavirin in non-responder patients with chronic hepatitis C. a randomized open-label pilot study. J Hepatol 44 (2006) 291-301